Search results
Results from the Tech24 Deals Content Network
A combination of PR-1 and WT-1 peptides has been tested by Rezvani et al. in a Phase I safety clinical trial for eight HLA-A*0201-positive patients with low-risk myeloid malignancies. [39,58] Five ...
A current Phase III trial is currently underway using the vaccinia-based prostate-specific antigen vaccine Prostvac-TRICOM. Other immunotherapeutic vaccines in trials include the Ad/prostate ...